Comparison of 68Ga-DOTA-NaI3-Octreotide/tyr3-octreotate positron emission tomography/computed tomography and contrast-enhanced computed tomography in localization of tumors in multiple endocrine neoplasia 1 syndrome

Virendra Patil; Manjunath Goroshi; Hina Shah; Gaurav Malhotra; Priya Hira; Vijaya Sarathi; Vikram Lele; Swati Jadhav; Anurag Lila; Tushar Bandgar; Nalini Shah

doi:10.4103/wjnm.WJNM_24_19

World Journal of Nuclear Medicine, Table of Contents

CC BY-NC-ND 4.0 · World J Nucl Med 2020; 19(02): 99-105
DOI: 10.4103/wjnm.WJNM_24_19

Original Article

Comparison of ⁶⁸Ga-DOTA-NaI³-Octreotide/tyr³-octreotate positron emission tomography/computed tomography and contrast-enhanced computed tomography in localization of tumors in multiple endocrine neoplasia 1 syndrome

Virendra Patil

Department of Endocrinology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra

,

Manjunath Goroshi

Department of Endocrinology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra

,

Hina Shah

¹Department of Nuclear Medicine and Positron Emission Tomography/Computed Tomography, Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India

,

Gaurav Malhotra

²Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre, Mumbai, Maharashtra, India

,

Priya Hira

³Department of Radiology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India

,

Vijaya Sarathi

⁴Department of Endocrinology, Narayana Medical College, Nellore, Andhra Pradesh, India

,

Vikram Lele

¹Department of Nuclear Medicine and Positron Emission Tomography/Computed Tomography, Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India

,

Swati Jadhav

Department of Endocrinology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra

,

Anurag Lila

Department of Endocrinology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra

,

Tushar Bandgar

Department of Endocrinology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra

,

Nalini Shah

Department of Endocrinology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra

› Author Affiliations

Abstract

The optimum imaging modality for the screening of multiple endocrine neoplasia type 1 (MEN1)-associated tumors is not well established. Here, we compare the performance of contrast-enhanced CT (CECT) versus ⁶⁸Ga DOTA-NOC/TATE PET/CT in MEN1 patients. The retrospective case record study is conducted at a tertiary health-care center. Thirty-four patients, who have undergone both CECT and ⁶⁸Ga DOTA-NOC/TATE PET, were included in the analysis. CECT had higher per-lesion sensitivity than ⁶⁸Ga DOTA-NOC/TATE PET/CT for the detection of parathyroid lesions, (82.6% vs. 24.6%, P < 0.001). ⁶⁸Ga DOTA-NOC/TATE PET/CT had higher per-lesion sensitivity than CECT for the detection of metastases (85% vs. 47.5%, P < 0.001) and gastrinomas (90% vs. 10%, P = 0.003). When combined use of the two imaging modalities is compared to CECT alone (63.7% vs. 93.1%, P = 0.00012) and ⁶⁸Ga-DOTA-NOC/TATE PET/CT alone (74.1% vs. 93.1%, P = 0.0057), it provided significantly higher per-lesion sensitivity for the detection of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). ⁶⁸Ga-DOTA-NOC/TATE PET was more sensitive for the detection of gastrinomas and metastases than CECT, whereas it was less sensitive for the detection of parathyroid lesions than CECT. The combined use of both the imaging modalities significantly increases the sensitivity for detection of GEP-NETs.

Keywords

⁶⁸Ga-DOTA-Nai³-octreotide/tyr³-octreotate positron emission tomography/computed tomography - contrast enhanced computed tomography - gastrointestinal-pancreatic neuroendocrine tumor - multiple endocrine neoplasia type 1 imaging - multiple endocrine neoplasia type 1 syndrome

Full Text

References

References
1 Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-71.
2 Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012;97:2990-3011.
3 Sadowski SM, Millo C, Cottle-Delisle C, Merkel R, Yang LA, Herscovitch P, et al. Results of (68)Gallium-DOTATATE PET/CT scanning in patients with multiple endocrine neoplasia type 1. J Am Coll Surg 2015;221:509-17.
4 Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V. Diagnostic performance of gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: A meta-analysis. Endocrine 2012;42:80-7.
5 Lastoria S, Marciello F, Faggiano A, Aloj L, Caracò C, Aurilio M, et al. Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1). Endocrine 2016;52:488-94.
6 Morgat C, Vélayoudom-Céphise FL, Schwartz P, Guyot M, Gaye D, Vimont D, et al. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1. Eur J Nucl Med Mol Imaging 2016;43:1258-66.
7 Froeling V, Elgeti F, Maurer MH, Scheurig-Muenkler C, Beck A, Kroencke TJ, et al. Impact of ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia. Ann Nucl Med 2012;26:738-43.
8 Lewis MA, Thompson GB, Young WF Jr. Preoperative assessment of the pancreas in multiple endocrine neoplasia type 1. World J Surg 2012;36:1375-81.
9 Goroshi M, Bandgar T, Lila AR, Jadhav SS, Khare S, Shrikhande SV, et al. Multiple endocrine neoplasia type 1 syndrome: Single centre experience from Western India. Fam Cancer 2016;15:617-24.
10 Baumann T, Rottenburger C, Nicolas G, Wild D. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) – Imaging and staging. Best Pract Res Clin Endocrinol Metab 2016;30:45-57.
11 Goroshi M, Lila AR, Jadhav SS, Sonawane S, Hira P, Goroshi S, et al. Percentage arterial enhancement: An objective index for accurate identification of parathyroid adenoma/hyperplasia in primary hyperparathyroidism. Clin Endocrinol (Oxf) 2017;87:791-8.
12 Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: Functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012;95:98-119.
13 Udelsman R, Škerström G, Biagini C, Duh QY, Miccoli P, Niederle B, et al. The surgical management of asymptomatic primary hyperparathyroidism: Proceedings of the fourth international workshop. J Clin Endocrinol Metab 2014;99:3595-606.
14 Ruda JM, Hollenbeak CS, Stack BC Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg 2005;132:359-72.
15 Lezaic L, Rep S, Sever MJ, Kocjan T, Hocevar M, Fettich J.1F-fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: A pilot study. Eur J Nucl Med Mol Imaging 2014;41:2083-9.
16 Hocevar M, Lezaic L, Rep S, Zaletel K, Kocjan T, Sever MJ, et al. Focused parathyroidectomy without intraoperative parathormone testing is safe after pre-operative localization with 18F-fluorocholine PET/CT. Eur J Surg Oncol 2017;43:133-7.
17 Ito T, Jensen RT. Imaging in multiple endocrine neoplasia type 1: Recent studies show enhanced sensitivities but increased controversies. Int J Endocr Oncol 2016;3:53-66.
18 Jia R, Sulentic P, Xu JM, Grossman AB. Thymic neuroendocrine neoplasms: Biological behaviour and therapy. Neuroendocrinology 2017;105:105-14.
19 van Essen M, Sundin A, Krenning EP, Kwekkeboom DJ. Neuroendocrine tumours: The role of imaging for diagnosis and therapy. Nat Rev Endocrinol 2014;10:102-14.
20 Marini F, Giusti F, Tonelli F, Brandi ML. Management impact: Effects on quality of life and prognosis in MEN1. Endocr Relat Cancer 2017;24:T227-T242.
21 Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: Clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics 2015;35:500-16.
22 Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34:982-93.
23 Casey RT, Saunders D, Challis BG, Pitfield D, Cheow H, Shaw A, et al. Radiological surveillance in multiple endocrine neoplasia type 1: A double-edged sword? Endocr Connect 2017;6:151-8.
24 Ruf J, Schiefer J, Furth C, Kosiek O, Kropf S, Heuck F, et al. 68Ga-DOTATOC PET/CT of neuroendocrine tumors: Spotlight on the CT phases of a triple-phase protocol. J Nucl Med 2011;52:697-704.
25 Sharma P, Naswa N, Kc SS, Alvarado LA, Dwivedi AK, Yadav Y, et al. Comparison of the prognostic values of 68Ga-DOTANOC PET/CT and ¹⁸F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor. Eur J Nucl Med Mol Imaging 2014;41:2194-202.